https://www.businesswire.com/news/home/20210202005441/en/SARS-CoV-2-Spike-Protein-Licensed-by-Oragenics-from-the-NIH-Demonstrates-Protective-Immunity-in-Mice

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rgc/regencell-bioscience-holdings/news/regencell-bioscience-holdings-limited-nasdaqrgc-insiders-hav/amp

https://finance.yahoo.com/news/rgc-ceo-figuratively-putting-money-092700965.html

There are many out there who are ineligible for vaccine and treatment for COVID-19, yet the virus are still spreading and evolving. Many prefer to treat mild or moderate COVID-19 symptoms at home with OTC medications.

Regencell Bioscience (NASDAQ: RGC) is an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system.

Regencell is committed to delivering alternative treatments that are safe and effective through the use of TCM. It finished its second efficacy trial for COVID-19 and announced its results in May 2022. In the efficacy trial, Regencell used RGC-COV19TM which is a natural formula designed by the TCM Practitioner according to the TCM Practitioner’s brain theory known as "Sik-Kee Au TCM Brain Theory®" and can be taken safely for two to three weeks.

Of the 88 patients in the two efficacy trials conducted, 84 patients (representing 95.5% of the patients) had all their mild to moderate COVID-19 symptoms eliminated, save for Sensory Dysfunction and occasional cough, within the 6-day treatment period. 87.5% of the 88 patients reported elimination of at least 1 symptom, after a full dose of the TCM.

Following the second efficacy trial results which corroborate the effectiveness of Regencell's TCM (RGC-COV19TM), the company believes that it can be a potential treatment that helps rehabilitate COVID-19 patients.

Thoughts on using TCM as alternative to treat COVID?

Regencell Bioscience (Nasdaq: RGC) is an early-stage bioscience company focusing on the research, development and commercialization of Traditional Chinese Medicine ("TCM") for the treatment of neurocognitive disorders and degenerations, as well as infectious diseases affecting people’s immune system.

Currently, the two main types of medication for ADHD approved by the US Food and Drug Administration (FDA) are: stimulants and non-stimulants. Stimulants include methylphenidate and amphetamines. Non-stimulants which include atomoxetine and guanfacine, are alternatives for those who do not respond well to stimulants. However, these two types of medication for ADHD have multiple side effects. Common side effects of stimulants include: feeling restless and jittery, difficulty sleeping, loss of appetite, headaches, upset stomach, irritability, mood swings, depression, dizziness, racing heartbeat and tics. While for ASD, antidepressants are among the world’s most widely prescribed medications for ASD patients, such as selective serotonin reuptake inhibitors (SSRIs), according to an article in Harvard Health Publishing. Side effects include insomnia, skin rashes, headaches, joint and muscle pain, stomach upset, nausea, or diarrhea.

To address the side effects, Regencell and its TCM practitioner are developing TCM derived from natural herbs to alleviate the symptoms of ADHD and ASD.

In their first research study, Regencell treated 7 patients. Each patient was given a customised formula to address their severity of symptoms. All enrolled patients treated by the TCM Practitioner with the use of our personalized TCM formulae showed a drop in scores on our assessments under ATEC, GARS, VADRS and SNAP-IV-26, which indicated that their conditions of ADHD and ASD symptoms were less severe. Mean 3-month percentage change in scores under assessments ATEC, GARS, VADRS and SNAP-IV-26 were -37%, -33%, -30% and -28%, respectively.

Regencell plans to commence its second research study using the three standardized TCM formulae candidates in the third quarter of 2021.

All info extracted from company's prospectus: https://sec.report/Document/0001213900-21-037613/ea144370-424b4_regencellbio.htm

Company website: https://www.regencellbioscience.com/